Several clinical trials are studying the effects of other BTK inhibitors such as evobrutinib, tirabrutinib (also called ONO/GS-4059) and AC0058TA for the treatment of systemic lupus erythematosus (SLE) and relapsing multiple sclerosis (MS) (www.clinicaltrials.gov) (3, 112, 118–120). Here, BTK is linked to systemic lupus erythematosus.